ExeVir Bio EIB funding case study

“We were delighted to work with Scius who collaboratively supported us as we announced our venture debt financing from the European Investment Bank. The coverage we received did a great job in highlighting the news and the capabilities of ExeVir in general including the potential of the company’s llama derived antibodies for protecting immunocompromised patients from COVID19.”

Torsten Mummenbrauer, CEO of ExeVir Bio

Objectives

To position ExeVir as a leading developer of novel antibody therapies that help immunocompromised patients to ward off infectious diseases
Announce significant (25 million Euro) financing from EIB to advance ExeVir’s COVID19 therapeutic
Highlight the experience of its world class leadership team

Strategy

Drafted announcement, and co-ordinated release and quotes from key stakeholders
Liaised with EIB around two complementary and aligned releases with mirroring quotes
Worked with translators and EIB contacts to ensure Belgian media received press release in local language (Dutch and French)
Pre-briefed target journalists under embargo and set up one-on-one briefings in advance of the news, with further media follow up on day of release

Results

Extensive global trade media coverage (Endpoints, BioWorld, Labiotech, and Silicon Canals)
National and broadcast Belgium press in French and Dutch language (La Libre, Nieuwsblad and Kanaal Z filming on site)

Objectives

Strategy

Results

Coverage

Social Media